-
VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate t
en-cphi.cn
May 10, 2017
New data confirms prior test results that Volition's novel blood test can accurately detect colorectal cancer and reduce colonoscopies
-
Immunocore and GSK identify second new ImmTAC for cancer treatment
pharmaceutical-technology
May 09, 2017
UK-based biotechnology firm Immunocore and GlaxoSmithKline (GSK) have identified a lead compound as part of their second discovery programme.
-
Pfizer offers breast cancer drug for free following NICE rejection
pharmafile
May 08, 2017
The drug was knocked back by NICE over concerns over the significance of its clinical efficacy in improving overall ...
-
Cheap blood test may help tailor prostate cancer treatment
pharmafile
May 05, 2017
A blood test that costs less than £50 to perform could prevent men from undergoing treatment with two drugs...
-
£50 blood test could predict prostate cancer drug response
pharmatimes
May 05, 2017
Researchers have developed a blood test that could better tailor the treatment of patients with prostate cancer.
-
AstraZeneca’s Imfinzi receives FDA-accelerated approval for urothelial cancer
pharmaceutical-technology
May 04, 2017
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) ...
-
Study discovers origin of cancer metastases and why they reoccur
pharmafile
May 04, 2017
A team of scientists from The Scripps Research Institute (TSRI) have discovered the secrets of where metastases...
-
Aeterna Zentaris’ endometrial cancer drug fails in Phase III
pharmatimes
May 04, 2017
A late stage clinical study of Aeterna Zentaris’ Zoptrex in women with locally advanced, recurrent or metastatic...
-
AZ’ Imfinzi gets accelerated nod for bladder cancer
pharmatimes
May 04, 2017
AstraZeneca has secured accelerated approval in the US for its immunotherapy Imfinzi as a treatment for certain patients with advanced bladder cancer.
-
England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'
worldpharmanews
May 03, 2017
Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the dru